M3, Inc.
2413・Prime Market・Services
Medical Platform
Pharmaceutical/medical DX marketing business built on a domestic base of over 350,000 physician members
| Period | Current | Previous | Change |
|---|---|---|---|
| Segment revenue (FY2026 (ending March 2026) full year) | ¥107,830 million | ¥91,566 million | ↑ |
| Segment profit (FY2026 (ending March 2026) full year) | ¥35,918 million | ¥34,105 million | ↑ |
| Segment profit margin (FY2026 (ending March 2026) full year) | 33.3% | 37.2% | ↓ |
| YoY revenue change (FY2026 (ending March 2026) full year) | +17.8% | — | ↑ |
| YoY segment profit change (FY2026 (ending March 2026) full year) | +5.3% | — | ↑ |
Business Details
Centered on "m3.com," a website for healthcare professionals, this segment operates marketing support for pharmaceutical companies (the "MR-kun" family), survey services targeting healthcare professionals, DX support for medical institutions including AI-equipped electronic medical records, third-party succession support for private practitioners, and corporate welfare services (through e-Well Inc.). Leveraging a platform with over 350,000 registered domestic physician members, it provides a diverse range of service menus to pharmaceutical companies, medical institutions, and general corporations.
Recent Overview
Revenue and profit increased, but margin declined due to an impairment loss recorded in the medical institution support business
For the full year of FY2026 (ending March 2026), segment revenue was ¥107,830 million (up 17.8% year on year), and segment profit was ¥35,918 million (up 5.3% year on year). The reduction of the negative impact from decreased COVID-19-related projects, steady performance in the pharmaceutical marketing support business and medical DX support business, and the contribution from the e-Well acquisition consolidated from April 2025 drove revenue growth. On the other hand, an impairment loss was recorded in the medical institution support business, causing the segment profit margin to decline from 37.2% in the prior period to 33.3%. Depreciation and amortization expenses increased significantly from ¥2,982 million in the prior period to ¥4,693 million (including the effect of e-Well consolidation).
Key Products
Growth Drivers
- Strengthening and promoting solution-oriented proposals that capture genuine DX demand from pharmaceutical companies (revenue and profit growth also expected in FY2027 (ending March 2027))
- Continued growth of the DX support business for medical institutions (AI-equipped electronic medical records, etc.)
- Reduction and elimination of the negative impact from the decrease in COVID-19-related projects
- Acquisition contribution and group synergies from e-Well Inc. (corporate welfare services), made a subsidiary in April 2025
- Continuous value enhancement of "m3.com," one of Japan's largest healthcare professional platforms with over 350,000 physician members
Risks
- Downward pressure on pharmaceutical marketing support-related revenue due to budget cuts by pharmaceutical companies
- Risk of deteriorating profitability and additional impairment losses in the medical institution support business (an impairment loss of ¥2,088 million was recorded in the current period as well)
- Intensifying competition and burden of implementation costs in the medical DX business (electronic medical records, etc.)
- Need for continuous investment in content and functionality to maintain and expand the m3.com member base
- Execution risk related to the integration and synergy realization of acquired subsidiaries (e-Well, etc.)
- Downward pressure on profit margin from increased depreciation and amortization expenses due to the consolidation of e-Well
Last updated: June 25, 2026